• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.50
  • 0.97 %
  • $426.14
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News & Analysis

Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, News & Analysis

Currency in USD Disclaimer

$10.14

-$0.11

(-1.03%)

Day's range
$10.05
Day's range
$10.29
50-day range
$8.03
Day's range
$11.44
  • Country: US
  • ISIN: US03969K1088
52 wk range
$1.76
Day's range
$13.17
  • CEO: Mr. Todd Franklin Watanabe M.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -1.24
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (ARQT)
  • Company Arcutis Biotherapeutics, Inc.
  • Price $10.14
  • Changes Percentage (-1.03%)
  • Change -$0.11
  • Day Low $10.05
  • Day High $10.29
  • Year High $13.17

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $27.50
  • High Stock Price Target $51.00
  • Low Stock Price Target $18.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.79
  • Trailing P/E Ratio -2.59
  • Forward P/E Ratio -2.59
  • P/E Growth -2.59
  • Net Income $-262,140,000

Income Statement

Quarterly

Annual

Latest News of ARQT

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Arcutis Biotherapeutics, Inc. Frequently Asked Questions

  • What were the earnings of ARQT in the last quarter?

    In the last quarter Arcutis Biotherapeutics, Inc. earnings were on Wednesday, November, 6th. The Arcutis Biotherapeutics, Inc. maker reported -$0.33 EPS for the quarter, beating analysts' consensus estimates of -$0.42 by $0.09.

  • What is the Arcutis Biotherapeutics, Inc. stock price today?

    Today's price of Arcutis Biotherapeutics, Inc. is $10.14 — it has decreased by -1.03% in the past 24 hours. Watch Arcutis Biotherapeutics, Inc. stock price performance more closely on the chart.

  • Does Arcutis Biotherapeutics, Inc. release reports?

    Yes, you can track Arcutis Biotherapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Arcutis Biotherapeutics, Inc. stock forecast?

    Watch the Arcutis Biotherapeutics, Inc. chart and read a more detailed Arcutis Biotherapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Arcutis Biotherapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Arcutis Biotherapeutics, Inc. stock ticker.

  • How to buy Arcutis Biotherapeutics, Inc. stocks?

    Like other stocks, ARQT shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Arcutis Biotherapeutics, Inc.'s EBITDA?

    Arcutis Biotherapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Arcutis Biotherapeutics, Inc.’s financial statements.

  • What is the Arcutis Biotherapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -4.3978794081, which equates to approximately -439.79%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Arcutis Biotherapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Arcutis Biotherapeutics, Inc.'s financials relevant news, and technical analysis. Arcutis Biotherapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Arcutis Biotherapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Arcutis Biotherapeutics, Inc.’s technical analysis.

  • A revenue figure for Arcutis Biotherapeutics, Inc. for its last quarter?

    Arcutis Biotherapeutics, Inc. published it's last quarterly revenues at $44.76 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.